Leerink Partnrs Comments on Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for Zai Lab in a research note issued on Thursday, February 27th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of $0.18 per share for the year. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

A number of other brokerages have also commented on ZLAB. Bank of America reiterated a "neutral" rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a report on Monday. Cantor Fitzgerald upgraded Zai Lab to a "strong-buy" rating in a research note on Wednesday, February 5th.

Zai Lab Stock Down 8.4 %

Shares of NASDAQ ZLAB traded down $2.91 during trading on Monday, reaching $31.73. 1,536,211 shares of the stock were exchanged, compared to its average volume of 889,028. The business's 50-day moving average price is $27.67 and its 200 day moving average price is $25.96. The company has a market capitalization of $3.47 billion, a price-to-earnings ratio of -11.45 and a beta of 1.02. Zai Lab has a twelve month low of $13.48 and a twelve month high of $36.60.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The company had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of the company's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the sale, the insider now owns 33,834 shares in the company, valued at approximately $889,157.52. This represents a 18.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.88% of the stock is currently owned by insiders.

Institutional Trading of Zai Lab

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in Zai Lab by 749.1% during the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock worth $143,403,000 after buying an additional 4,830,646 shares during the last quarter. RTW Investments LP acquired a new position in Zai Lab in the fourth quarter worth $65,714,000. Janus Henderson Group PLC boosted its holdings in Zai Lab by 34.2% in the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock worth $211,488,000 after purchasing an additional 2,232,507 shares during the period. Principal Financial Group Inc. bought a new stake in Zai Lab during the fourth quarter valued at $46,172,000. Finally, Wellington Management Group LLP raised its holdings in shares of Zai Lab by 18.4% during the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company's stock worth $203,660,000 after purchasing an additional 1,312,115 shares during the period. 41.65% of the stock is owned by institutional investors.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.